UNCY

Unicycive Therapeutics (UNCY)

Unicycive Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:UNCY

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/25	20 : 30	GlobeNewswire Inc.	Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/28	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/23	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/15	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/14	05 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/14	05 : 16	GlobeNewswire Inc.	Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/14	05 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/05/09	05 : 05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/04/10	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/29	05 : 15	GlobeNewswire Inc.	Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/25	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/14	20 : 03	GlobeNewswire Inc.	Unicycive Announces $50 Million Private Placement	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/13	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/08	06 : 12	GlobeNewswire Inc.	Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/03/04	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/02/22	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/02/14	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/01/29	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/01/23	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones	NASDAQ:UNCY	Unicycive Therapeutics Inc
2024/01/23	06 : 27	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/12/18	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/12/09	06 : 36	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/11/29	21 : 03	GlobeNewswire Inc.	Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/11/15	06 : 20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/11/15	06 : 15	GlobeNewswire Inc.	Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/10/24	00 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/10/23	20 : 03	GlobeNewswire Inc.	Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/09/26	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/09/08	05 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:UNCY	Unicycive Therapeutics Inc
2023/09/08	05 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:UNCY	Unicycive Therapeutics Inc